BNTX:NASDAQ
BioNTech SE - ADR
US$ ९६.९०
arrow_upward
+०.०५%(+०.०५०) 1D
US$ ९६.१४
arrow_downward
-०.७८% (-०.७६)todayPre-market
Closed: अक्टोबर २, १६:००:०१ GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
US$ ९७.३५
High
US$ ९८.००
Low
US$ ९६.२२
Mkt. cap
२४.३४ अरब
Avg. vol.
११.९० लाख
Volume
१.४४ हजार
52-wk high
US$ १२३.९८
52-wk low
US$ ७९.५२
EPS
-US$ ७.५५
Beta
१.२२
Shares outstanding
२५.१२ करोड
No. of employees
८ हजार
Open
US$ ९७.३५
High
US$ ९८.००
Low
US$ ९६.२२
Mkt. cap
२४.३४ अरब
Avg. vol.
११.९० लाख
Volume
१.४४ हजार
52-wk high
US$ १२३.९८
52-wk low
US$ ७९.५२
EPS
-US$ ७.५५
Beta
१.२२
Shares outstanding
२५.१२ करोड
No. of employees
८ हजार
News stories
From web sources and news partners
AD HOC NEWS
·
२ घण्टा पहिले
Berenberg raises target for BioNTech stock from USD 132 to USD 140
AD HOC NEWS
·
१८ घण्टा पहिले
BioNTech stock faces a 59.5 percent Q2 revenue drop
Seeking Alpha
·
२० घण्टा पहिले
BioNTech SE: Moving Past Covid (NASDAQ:BNTX)
AD HOC NEWS
·
१ दिन पहिले
CureVac stock converts into BioNTech shares after merger
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR